Germany’s drug-price cut
Berlin tied price cuts to a drug’s revenue. Lilly halved a German factory. Washington opened a 301. The formula went away. The rate did not.
In April, Germany used the price of a pill to close a budget gap. Tess Cameron, on Biotech Hangout in June, put it in one sentence: the more revenue a drug earned, the deeper the mandated cut. Eli Lilly answered by shrinking a factory. On June 18 the United States Trade Representative opened a Section 301 investigation into those policies. The chain is short, dated, and runs through a capital-allocation decision — not through a pen, a PDUFA clock, or a chip tariff.
The USTR docket names two German instruments. One is a confidentiality-conditioned mandatory 9 percent price reduction. The other is a 2026 draft that industry models said could become a variable rebate approaching 20 percent by 2030. The Federal Register frames the harm the way Washington always frames it: American patients underwriting a disproportionate share of global pharmaceutical research. The German legislative text itself is still not sitting on the wiki. The 9 and 20 percent figures are the USTR’s and industry’s characterization.
Germany came out with a… policy in April where they said… we’re going to use drug pricing to close the funding gap in our budget… if you make more revenue as a drug… we’re going to… cut the price more.
Tess Cameron, Biotech Hangout, June 2026
The factory was the transmission
Lilly’s Alzey project was the €2.3 billion answer to a European plant. A company spokesperson later told Fierce the firm could “no longer commit to the full vision for Alzey” and expected to cut the scope “by 50% or more versus the original announcement.” That is not an 8-K. It is the transmission the wiki has: a capital decision, reported second-hand, sitting between a German price rule and an American trade docket.
The investigation is the confirmed step. USTR-2026-0463 and USTR-2026-0464 opened June 18. The Federal Register notice ran June 24. Written comments were due August 10. A public hearing was noticed for September 22 at 10:00 a.m. at the International Trade Commission. The wiki, as of the September 19 recheck, does not record what was said in the room. The parallel Section 232 pharmaceutical-tariff regime is a second lever pointed at the same names. It is not this chain.
The formula left. The rate stayed.
On July 10 the German bill, GKV-BStabG, dropped the dynamic rebate. In its place: a fixed manufacturer rebate of 15.5 percent — 7 percent plus 8.5 points — from January 1, 2027. That is a formula back-down and a rate tightening at the same time. Cameron’s June rumor was that Berlin might “back off.” The draft’s variable path toward 20 percent is gone. The cash taken from a high-revenue drug is not.
Two German rebate stories
The 20 percent figure is industry’s model of a draft that was struck. The 15.5 percent is the July 10 statute. Both sit on the stock-market wiki’s 301 chain.
Reuters had Germany “rethinking” in mid-June, before the July rewrite. Causal “the 301 made Berlin fold” is not established. The beneficiary is diffuse — every US drugmaker with material German or EU revenue — which is why the wiki files this as a monitor, not a Lilly re-rate. The Houston Foundayo groundbreaking is a different factory and a different article. So is the GLP-1 pen. So is the FDA rare-disease clock. The 301 instrument pointed at German pricing is not the chip-tariff shield.